PMID: 15223801Jun 30, 2004Paper

Effect of latanoprost on outflow facility in the mouse

Investigative Ophthalmology & Visual Science
Jonathan G CrowstonRobert N Weinreb

Abstract

To assess the early effect of latanoprost on outflow facility and aqueous humor dynamics in the mouse. Aqueous humor dynamics in NIH Swiss White mice were assessed with an injection and aspiration system, using fine glass microneedles. A single 200-ng (4 microL) dose of latanoprost was applied to one eye 2 hours before measurement. The fellow eye served as a control. Intraocular pressure (IOP) was measured by using an established microneedle procedure. Outflow facility (C) was determined by constant-pressure perfusion measurements obtained at two different IOPs. Aqueous humor flow (Fa) was determined by a dilution method using rhodamine-dextran. Conventional and uveoscleral outflow (Fc and Fu) were calculated by the Goldmann equation. Average IOP, Fa, and C of control eyes were 15.7 +/- 1.0 mm Hg, 0.144 +/- 0.04 microL/min (mean +/- SD, n = 8), and 0.0053 +/- 0.0014 microL/min per mm Hg (n = 21), respectively. Average IOP, Fa, and C of treated eyes were 14.0 +/- 0.8 mm Hg, 0.138 +/- 0.04 microL/min (n = 8 for each), and 0.0074 +/- 0.0016 microL/min per mm Hg (n = 21), respectively. The differences between treated and control eyes were significant for IOP and total outflow facility only. These data indicate that the early hypote...Continue Reading

Citations

Oct 28, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Mei TsudaMiyo Matsumura
Mar 4, 2005·Current Opinion in Ophthalmology·Jonathan G Crowston, Robert N Weinreb
Jul 2, 2005·Journal of Glaucoma·James D Lindsey, Robert N Weinreb
Nov 25, 2006·The British Journal of Ophthalmology·Takashi OtaMakoto Araie
Feb 21, 2013·Investigative Ophthalmology & Visual Science·Swarup S SwaminathanDouglas J Rhee
Sep 10, 2014·The Journal of Clinical Investigation·Benjamin R ThomsonSusan E Quaggin
Feb 7, 2016·Experimental Eye Research·Mark JohnsonDarryl R Overby
Dec 17, 2008·Survey of Ophthalmology·Carol B TorisPaul L Kaufman
Jan 12, 2008·Experimental Eye Research·Mingcong WangJunko Hori
Dec 2, 2011·Veterinary Ophthalmology·Susan TsaiMichael R Robinson
Jan 27, 2005·Experimental Eye Research·Iok-Hou PangAbbot F Clark
Oct 10, 2006·Experimental Eye Research·Shahid HusainCraig E Crosson
Feb 10, 2006·Experimental Eye Research·Christy A MorrisRobert N Weinreb
Sep 21, 2013·Translational Vision Science & Technology·Alex L C TamYeni H Yücel
Mar 29, 2011·Experimental Eye Research·Murray JohnstoneAnnisa Jamil
Jul 28, 2016·Experimental Eye Research·Ilya RybkinJohn Danias
Mar 8, 2016·PloS One·Joseph M SherwoodDarryl R Overby
Aug 3, 2016·Disease Models & Mechanisms·K Saidas NairSimon W M John
Nov 17, 2017·Biomedicine Hub·Aleksandr YelenskiyJames C Tan
Sep 19, 2017·The Journal of Clinical Investigation·Jaeryung KimGou Young Koh
Jun 4, 2018·Investigative Ophthalmology & Visual Science·Yeni H YücelNeeru Gupta
Aug 28, 2010·Current Eye Research·Lucinda J CamrasCarol B Toris
Nov 10, 2020·Experimental Eye Research·Vickie H Y WongChristine T O Nguyen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.